These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
CARDLYTICS, INC.
|
|
|
(Exact Name of Registrant as Specified in its Charter)
|
|
|
Delaware
|
26-3039436
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
675 Ponce de Leon Ave. NE, Ste 6000, Atlanta, GA 30308
|
(888) 798-5802
|
|
(Address of principal executive offices, including zip code)
|
(Registrant’s telephone number, including area code)
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
Non-accelerated filer
|
|
☒ (Do not check if a small reporting company)
|
|
Small reporting company
|
|
☐
|
|
Emerging growth company
|
|
☒
|
|
|
|
|
|
|
|
|
|
Page
|
|
PART I.
|
FINANCIAL INFORMATION
|
|
|
Item 1.
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
PART II.
|
OTHER INFORMATION
|
|
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 6.
|
||
|
CARDLYTICS, INC.
(Amounts in thousands, except par value amounts)
|
|||||||
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
ASSETS
|
|
|
|
||||
|
CURRENT ASSETS:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
21,262
|
|
|
$
|
89,785
|
|
|
Accounts receivable, net
|
48,348
|
|
|
39,907
|
|
||
|
Other receivables
|
2,898
|
|
|
2,748
|
|
||
|
Prepaid expenses and other assets
|
2,121
|
|
|
3,658
|
|
||
|
Total current assets
|
$
|
74,629
|
|
|
$
|
136,098
|
|
|
PROPERTY AND EQUIPMENT, net
|
7,319
|
|
|
7,363
|
|
||
|
INTANGIBLE ASSETS, net
|
528
|
|
|
359
|
|
||
|
CAPITALIZED SOFTWARE DEVELOPMENT COSTS, net
|
433
|
|
|
880
|
|
||
|
DEFERRED FI IMPLEMENTATION COSTS, net
|
13,625
|
|
|
12,119
|
|
||
|
OTHER LONG-TERM ASSETS
|
4,224
|
|
|
988
|
|
||
|
Total assets
|
$
|
100,758
|
|
|
$
|
157,807
|
|
|
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
|
|
|
|
||||
|
CURRENT LIABILITIES:
|
|
|
|
||||
|
Accounts payable
|
$
|
1,554
|
|
|
$
|
1,783
|
|
|
Accrued liabilities:
|
|
|
|
||||
|
Accrued compensation
|
4,638
|
|
|
3,263
|
|
||
|
Accrued expenses
|
4,615
|
|
|
3,918
|
|
||
|
FI Share liability
|
23,914
|
|
|
21,376
|
|
||
|
Consumer Incentive liability
|
7,242
|
|
|
6,949
|
|
||
|
Deferred billings
|
132
|
|
|
189
|
|
||
|
Short-term warrant liability
|
—
|
|
|
17,666
|
|
||
|
Short-term debt:
|
|
|
|
||||
|
Line of credit
|
—
|
|
|
25,634
|
|
||
|
Capital leases
|
44
|
|
|
23
|
|
||
|
Total current liabilities
|
$
|
42,139
|
|
|
$
|
80,801
|
|
|
LONG-TERM LIABILITIES:
|
|
|
|
||||
|
Deferred liabilities
|
$
|
3,670
|
|
|
$
|
3,554
|
|
|
Long-term warrant liability
|
10,230
|
|
|
—
|
|
||
|
Long-term debt, net of current portion:
|
|
|
|
||||
|
Line of credit
|
25,081
|
|
|
—
|
|
||
|
Term loan
|
31,830
|
|
|
32,842
|
|
||
|
Capital leases
|
57
|
|
|
52
|
|
||
|
Total long-term liabilities
|
$
|
70,868
|
|
|
$
|
36,448
|
|
|
CARDLYTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except par value amounts)
|
|||||||
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
|
|
|
|
||||
|
COMMITMENTS AND CONTINGENCIES (Note 8)
|
|
|
|
||||
|
REDEEMABLE CONVERTIBLE PREFERRED STOCK:
|
|
|
|
||||
|
Series G’ preferred stock, $0.0001 par value—5,339 shares authorized and 1,295 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
$
|
44,672
|
|
|
$
|
—
|
|
|
Series G preferred stock, $0.0001 par value—1,385 shares authorized and 346 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
5,110
|
|
|
—
|
|
||
|
Series F-R preferred stock, $0.0001 par value—5,000 shares authorized and 1,199 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
58,449
|
|
|
—
|
|
||
|
Series E-R preferred stock, $0.0001 par value— 7,400 shares authorized and 795 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
29,972
|
|
|
—
|
|
||
|
Series D-R preferred stock, $0.0001 par value—5,787 shares authorized and 1,396 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
32,728
|
|
|
—
|
|
||
|
Series C-R preferred stock, $0.0001 par value—6,032 shares authorized and 1,508 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
18,366
|
|
|
—
|
|
||
|
Series B-R preferred stock, $0.0001 par value—9,596 shares authorized and 2,247 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
5,288
|
|
|
—
|
|
||
|
Series A-R preferred stock, $0.0001 par value—7,528 shares authorized and 1,857 shares issued and outstanding as of December 31, 2017, no shares authorized, issued or outstanding as of March 31, 2018
|
1,852
|
|
|
—
|
|
||
|
Total redeemable convertible preferred stock
|
$
|
196,437
|
|
|
$
|
—
|
|
|
STOCKHOLDERS’ (DEFICIT) EQUITY:
|
|
|
|
||||
|
Common stock, $0.0001 par value—83,000 and 100,000 shares authorized and 3,439 and 20,226 shares issued and outstanding as of December 31, 2017 and March 31, 2018, respectively
|
$
|
—
|
|
|
$
|
7
|
|
|
Additional paid-in capital
|
58,693
|
|
|
328,493
|
|
||
|
Accumulated other comprehensive income
|
1,066
|
|
|
558
|
|
||
|
Accumulated deficit
|
(268,445
|
)
|
|
(288,500
|
)
|
||
|
Total stockholders’ (deficit) equity
|
(208,686
|
)
|
|
40,558
|
|
||
|
Total liabilities and stockholders’ (deficit) equity
|
$
|
100,758
|
|
|
$
|
157,807
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
REVENUE
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
COSTS AND EXPENSES:
|
|
|
|
||||
|
FI Share and other third-party costs
|
16,677
|
|
|
21,420
|
|
||
|
Delivery costs
|
1,553
|
|
|
1,943
|
|
||
|
Sales and marketing expense
|
7,232
|
|
|
8,216
|
|
||
|
Research and development expense
|
3,013
|
|
|
3,459
|
|
||
|
General and administration expense
|
4,689
|
|
|
6,582
|
|
||
|
Depreciation and amortization expense
|
765
|
|
|
910
|
|
||
|
Total costs and expenses
|
33,929
|
|
|
42,530
|
|
||
|
OPERATING LOSS
|
(7,048
|
)
|
|
(9,817
|
)
|
||
|
OTHER INCOME (EXPENSE):
|
|
|
|
||||
|
Interest expense, net
|
(2,644
|
)
|
|
(1,749
|
)
|
||
|
Change in fair value of warrant liabilities, net
|
(327
|
)
|
|
(9,172
|
)
|
||
|
Change in fair value of convertible promissory notes
|
(383
|
)
|
|
—
|
|
||
|
Change in fair value of convertible promissory notes—related parties
|
(2,223
|
)
|
|
—
|
|
||
|
Other income, net
|
162
|
|
|
683
|
|
||
|
Total other expense
|
(5,415
|
)
|
|
(10,238
|
)
|
||
|
LOSS BEFORE INCOME TAXES
|
(12,463
|
)
|
|
(20,055
|
)
|
||
|
INCOME TAX BENEFIT
|
—
|
|
|
—
|
|
||
|
NET LOSS
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
Adjustments to the carrying value of redeemable convertible preferred stock
|
(244
|
)
|
|
(157
|
)
|
||
|
Net loss attributable to common stockholders
|
$
|
(12,707
|
)
|
|
$
|
(20,212
|
)
|
|
Net loss per share attributable to common stockholders, basic and diluted
|
$
|
(4.80
|
)
|
|
$
|
(1.54
|
)
|
|
Weighted-average common shares outstanding, basic and diluted
|
2,645
|
|
|
13,093
|
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
NET LOSS
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
OTHER COMPREHENSIVE LOSS:
|
|
|
|
||||
|
Foreign currency translation adjustments
|
(120
|
)
|
|
(508
|
)
|
||
|
TOTAL COMPREHENSIVE LOSS
|
$
|
(12,583
|
)
|
|
$
|
(20,563
|
)
|
|
|
|
|
Additional
Paid-In
Capital
|
|
Accumulated
Other
Comprehensive
Income
|
|
Accumulated
Deficit
|
|
Total
|
|||||||||||||
|
|
Common Stock
|
|
||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
||||||||||||||||||
|
BALANCE–December 31, 2017
|
3,439
|
|
|
$
|
—
|
|
|
$
|
58,693
|
|
|
$
|
1,066
|
|
|
$
|
(268,445
|
)
|
|
$
|
(208,686
|
)
|
|
Exercise of common stock options
|
26
|
|
|
—
|
|
|
108
|
|
|
—
|
|
|
—
|
|
|
108
|
|
|||||
|
Exercise of common stock warrants
|
297
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
2,906
|
|
|
—
|
|
|
—
|
|
|
2,906
|
|
|||||
|
Issuance of common stock in connection with our IPO
|
5,821
|
|
|
1
|
|
|
66,100
|
|
|
—
|
|
|
—
|
|
|
66,101
|
|
|||||
|
Vesting of performance-based common stock warrants
|
—
|
|
|
—
|
|
|
2,519
|
|
|
—
|
|
|
—
|
|
|
2,519
|
|
|||||
|
Conversion of preferred stock to common stock
|
10,643
|
|
|
6
|
|
|
196,588
|
|
|
—
|
|
|
—
|
|
|
196,594
|
|
|||||
|
Conversion of preferred stock warrants to common stock warrants
|
—
|
|
|
—
|
|
|
1,736
|
|
|
—
|
|
|
—
|
|
|
1,736
|
|
|||||
|
Accretion of redeemable convertible preferred stock to redemption value
|
—
|
|
|
—
|
|
|
(157
|
)
|
|
—
|
|
|
—
|
|
|
(157
|
)
|
|||||
|
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(508
|
)
|
|
—
|
|
|
(508
|
)
|
|||||
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(20,055
|
)
|
|
(20,055
|
)
|
|||||
|
BALANCE–March 31, 2018
|
20,226
|
|
|
$
|
7
|
|
|
$
|
328,493
|
|
|
$
|
558
|
|
|
$
|
(288,500
|
)
|
|
$
|
40,558
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
||||
|
Net loss
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
|
Change in allowance for doubtful accounts
|
(4
|
)
|
|
(32
|
)
|
||
|
Depreciation and amortization
|
765
|
|
|
910
|
|
||
|
Amortization of financing costs charged to interest expense
|
148
|
|
|
140
|
|
||
|
Accretion of debt discount and non-cash interest expense
|
2,307
|
|
|
1,500
|
|
||
|
Stock compensation expense
|
983
|
|
|
2,900
|
|
||
|
Change in the fair value of warrant liabilities, net
|
327
|
|
|
9,172
|
|
||
|
Change in the fair value of convertible promissory notes
|
383
|
|
|
—
|
|
||
|
Change in the fair value of convertible promissory notes - related parties
|
2,223
|
|
|
—
|
|
||
|
Other non-cash expenses
|
229
|
|
|
2,253
|
|
||
|
Change in operating assets and liabilities:
|
|
|
|
||||
|
Accounts receivable
|
6,672
|
|
|
8,623
|
|
||
|
Prepaid expenses and other assets
|
(551
|
)
|
|
(1,520
|
)
|
||
|
Deferred FI implementation costs
|
962
|
|
|
1,094
|
|
||
|
Accounts payable
|
631
|
|
|
(408
|
)
|
||
|
Other accrued expenses
|
(2,802
|
)
|
|
(1,836
|
)
|
||
|
FI Share liability
|
(4,643
|
)
|
|
(2,538
|
)
|
||
|
Customer Incentive liability
|
(991
|
)
|
|
(293
|
)
|
||
|
Total adjustment
|
6,639
|
|
|
19,965
|
|
||
|
Net cash used in operating activities
|
$
|
(5,824
|
)
|
|
$
|
(90
|
)
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
||||
|
Acquisition of property and equipment
|
$
|
(386
|
)
|
|
$
|
(418
|
)
|
|
Acquisition of patents
|
(16
|
)
|
|
(2
|
)
|
||
|
Capitalized software development costs
|
—
|
|
|
(374
|
)
|
||
|
Net cash used in investing activities
|
$
|
(402
|
)
|
|
$
|
(794
|
)
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
||||
|
Proceeds from issuance of debt
|
$
|
7,500
|
|
|
$
|
—
|
|
|
Principal payments of debt
|
(24
|
)
|
|
(26
|
)
|
||
|
Proceeds from issuance of common stock
|
270
|
|
|
70,490
|
|
||
|
Equity issuance costs
|
(181
|
)
|
|
(1,232
|
)
|
||
|
Net cash from financing activities
|
$
|
7,565
|
|
|
$
|
69,232
|
|
|
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH
|
46
|
|
|
175
|
|
||
|
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
|
1,385
|
|
|
68,523
|
|
||
|
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period
|
22,968
|
|
|
21,262
|
|
||
|
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—end of period
|
$
|
24,353
|
|
|
$
|
89,785
|
|
|
Supplemental schedule of non-cash investing and financing activities:
|
|
|
|
||||
|
Cash paid for interest
|
$
|
188
|
|
|
$
|
247
|
|
|
Amounts accrued for property and equipment
|
$
|
15
|
|
|
$
|
1,155
|
|
|
Amounts accrued for capitalized software development costs
|
$
|
—
|
|
|
$
|
141
|
|
|
Stock-based compensation capitalized for software development
|
$
|
—
|
|
|
$
|
6
|
|
|
|
December 31,
|
|
March 31,
|
||||||||||||
|
|
2016
|
|
2017
|
|
2017
|
|
2018
|
||||||||
|
Cash and cash equivalents
|
$
|
22,838
|
|
|
$
|
21,262
|
|
|
$
|
24,353
|
|
|
$
|
89,785
|
|
|
Restricted cash
|
130
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Cash, cash equivalents and restricted cash
|
$
|
22,968
|
|
|
$
|
21,262
|
|
|
$
|
24,353
|
|
|
$
|
89,785
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Beginning balance
|
$
|
—
|
|
|
$
|
3,144
|
|
|
Deferred costs
|
776
|
|
|
1,135
|
|
||
|
Recognized against offering proceeds
|
—
|
|
|
(4,279
|
)
|
||
|
Ending balance
|
$
|
776
|
|
|
$
|
—
|
|
|
•
|
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
|
|
•
|
Level 2 inputs are inputs other than Level 1 inputs such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
|
|
•
|
Level 3 inputs are unobservable inputs for the asset or liability.
|
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
Line of credit
|
$
|
25,081
|
|
|
$
|
25,634
|
|
|
Term loan, net of unamortized discount and debt issuance costs of $1,058 and $889 at December 31, 2017 and March 31, 2018, respectively
|
31,830
|
|
|
32,842
|
|
||
|
Capital leases
|
101
|
|
|
75
|
|
||
|
Convertible promissory notes (converted into Series G' Stock in May 2017)
|
—
|
|
|
—
|
|
||
|
Total debt
|
$
|
57,012
|
|
|
$
|
58,551
|
|
|
Less short-term debt
|
(44
|
)
|
|
(25,657
|
)
|
||
|
Long-term debt, net of current portion
|
$
|
56,968
|
|
|
$
|
32,894
|
|
|
Years Ending December 31,
|
Debt
|
|
Capital Leases
|
|
Total Debt
|
||||||
|
2018 (remainder of year)
|
$
|
—
|
|
|
$
|
18
|
|
|
$
|
18
|
|
|
2019
|
59,365
|
|
|
20
|
|
|
59,385
|
|
|||
|
2020
|
—
|
|
|
24
|
|
|
24
|
|
|||
|
2021
|
—
|
|
|
13
|
|
|
13
|
|
|||
|
Total principal payments
|
$
|
59,365
|
|
|
$
|
75
|
|
|
$
|
59,440
|
|
|
Less unamortized debt issuance costs
|
(274
|
)
|
|
—
|
|
|
(274
|
)
|
|||
|
Less unamortized debt discount
|
(615
|
)
|
|
—
|
|
|
(615
|
)
|
|||
|
Total debt
|
$
|
58,476
|
|
|
$
|
75
|
|
|
$
|
58,551
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Delivery costs
|
$
|
41
|
|
|
$
|
85
|
|
|
Sales and marketing expense
|
344
|
|
|
943
|
|
||
|
Research and development expense
|
171
|
|
|
470
|
|
||
|
General and administration expense
|
427
|
|
|
1,402
|
|
||
|
Total stock-based compensation expense
|
$
|
983
|
|
|
$
|
2,900
|
|
|
|
Shares
|
|
Weighted-Average Exercise Price
|
|||
|
Options outstanding — December 31, 2016
|
2,137
|
|
|
$
|
15.00
|
|
|
Granted
|
124
|
|
|
11.81
|
|
|
|
Exercised
|
(76
|
)
|
|
3.57
|
|
|
|
Forfeited
|
(9
|
)
|
|
20.59
|
|
|
|
Cancelled
|
(6
|
)
|
|
14.21
|
|
|
|
Options outstanding — March 31, 2017
|
2,170
|
|
|
$
|
15.20
|
|
|
|
Shares
|
|
Weighted-Average Exercise Price
|
|||
|
Options outstanding — December 31, 2017
|
2,514
|
|
|
$
|
18.42
|
|
|
Granted
|
29
|
|
|
24.24
|
|
|
|
Exercised
|
(26
|
)
|
|
4.22
|
|
|
|
Forfeited
|
(103
|
)
|
|
25.65
|
|
|
|
Cancelled
|
(35
|
)
|
|
15.88
|
|
|
|
Options outstanding — March 31, 2018
|
2,379
|
|
|
$
|
18.37
|
|
|
|
Shares
|
|
Weighted-Average Grant Date Fair Value
|
|||
|
Unvested — December 31, 2017
|
—
|
|
|
$
|
—
|
|
|
Granted
|
1,210
|
|
|
20.80
|
|
|
|
Vested
|
—
|
|
|
—
|
|
|
|
Forfeited
|
(2
|
)
|
|
16.80
|
|
|
|
Unvested — March 31, 2018
|
1,208
|
|
|
$
|
20.81
|
|
|
|
Series G’ Stock
|
|
Series G Stock
|
||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
||||||
|
Balance — December 31, 2017
|
1,295
|
|
|
$
|
44,672
|
|
|
346
|
|
|
$
|
5,110
|
|
|
Accretion of redeemable convertible preferred stock
|
—
|
|
|
—
|
|
|
—
|
|
|
108
|
|
||
|
Conversion of preferred stock to common stock
|
(1,295
|
)
|
|
(44,672
|
)
|
|
(346
|
)
|
|
(5,218
|
)
|
||
|
Balance — March 31, 2018
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
|
Series F-R Stock
|
|
Series E-R Stock
|
|
Series D-R Stock
|
|||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|||||||||
|
Balance — December 31, 2017
|
1,199
|
|
|
$
|
58,449
|
|
|
795
|
|
|
$
|
29,972
|
|
|
1,396
|
|
|
$
|
32,728
|
|
|
Accretion of redeemable convertible preferred stock
|
—
|
|
|
38
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
7
|
|
|||
|
Conversion of preferred stock to common stock
|
(1,199
|
)
|
|
(58,487
|
)
|
|
(795
|
)
|
|
(29,973
|
)
|
|
(1,396
|
)
|
|
(32,735
|
)
|
|||
|
Balance — March 31, 2018
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
|
Series C-R Stock
|
|
Series B-R Stock
|
|
Series A-R Stock
|
|||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|||||||||
|
Balance — December 31, 2017
|
1,508
|
|
|
$
|
18,366
|
|
|
2,247
|
|
|
$
|
5,288
|
|
|
1,857
|
|
|
$
|
1,852
|
|
|
Accretion of redeemable convertible preferred stock
|
—
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
Conversion of preferred stock to common stock
|
(1,508
|
)
|
|
(18,369
|
)
|
|
(2,247
|
)
|
|
(5,288
|
)
|
|
(1,857
|
)
|
|
(1,852
|
)
|
|||
|
Balance — March 31, 2018
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
|
December 31, 2017
|
||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
|
Preferred stock warrants
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,285
|
|
|
$
|
2,285
|
|
|
Common stock warrants
|
—
|
|
|
—
|
|
|
7,945
|
|
|
7,945
|
|
||||
|
Convertible promissory notes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
10,230
|
|
|
$
|
10,230
|
|
|
|
March 31, 2018
|
||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
|
Preferred stock warrants
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Common stock warrants
|
—
|
|
|
—
|
|
|
17,666
|
|
|
17,666
|
|
||||
|
Convertible promissory notes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
17,666
|
|
|
$
|
17,666
|
|
|
|
Preferred
Stock
Warrants
|
|
Common
Stock
Warrants
|
|
Convertible
Promissory
Notes
|
||||||
|
Balance at December 31, 2016
|
$
|
2,197
|
|
|
$
|
—
|
|
|
$
|
72,332
|
|
|
Accrued interest on convertible promissory notes
|
—
|
|
|
—
|
|
|
1,246
|
|
|||
|
Changes in fair value
|
327
|
|
|
—
|
|
|
2,606
|
|
|||
|
Balance at March 31, 2017
|
$
|
2,524
|
|
|
$
|
—
|
|
|
$
|
76,184
|
|
|
|
Preferred
Stock
Warrants
|
|
Common
Stock
Warrants
|
|
Convertible
Promissory
Notes
|
||||||
|
Balance at December 31, 2017
|
$
|
2,285
|
|
|
$
|
7,945
|
|
|
$
|
—
|
|
|
Changes in fair value
|
(549
|
)
|
|
9,721
|
|
|
—
|
|
|||
|
Conversion of preferred stock warrants to common stock warrants
|
(1,736
|
)
|
|
—
|
|
|
—
|
|
|||
|
Balance at March 31, 2018
|
$
|
—
|
|
|
$
|
17,666
|
|
|
$
|
—
|
|
|
|
March 31, 2017
|
|
Cost of debt applicable to convertible promissory notes
|
10%
|
|
Cost of equity applicable to convertible promissory notes
|
22%
|
|
Weighted-average cost of capital applicable to preferred stock warrants
|
23%
|
|
Discount for lack of marketability
|
7% to 11%
|
|
Volatility
|
53%
|
|
Risk-free interest rate
|
0.7% to 1.2%
|
|
Preferred Series
|
Grant
date
|
|
Expiration
date
|
|
Exercise
price
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
Series B-R
|
2/26/2010
|
|
2/25/2020
|
|
$
|
2.36
|
|
|
59
|
|
|
—
|
|
|
Series D-R
|
9/21/2012
|
|
9/20/2022
|
|
$
|
23.64
|
|
|
38
|
|
|
—
|
|
|
Series D-R
|
9/21/2012
|
|
9/20/2022
|
|
$
|
23.64
|
|
|
13
|
|
|
—
|
|
|
Total
|
|
|
|
|
|
|
110
|
|
|
—
|
|
||
|
|
Performance-based warrants
(vested upon IPO)
|
|
Weighted-average grant date fair value
|
$3.91
|
|
Significant inputs:
|
|
|
Value of common stock
|
$13.00
|
|
Expected term
|
5.3 years
|
|
Volatility
|
50%
|
|
Risk-free interest rate
|
2.0%
|
|
Dividend yield
|
—%
|
|
Related Party
|
Shares of
Series G
Preferred
Stock
|
|
Shares of
Series G’
Preferred
Stock
|
|
Shares of
Common
Stock
|
|
Warrants to
Purchase
Common
Stock
|
||||
|
Entities affiliated with Aimia, Inc.
(1)
|
—
|
|
|
382
|
|
|
801
|
|
|
—
|
|
|
Entities affiliated with Polaris Venture Partners
(2)
|
29
|
|
|
212
|
|
|
—
|
|
|
(6
|
)
|
|
Canaan VIII L.P.
(3)
|
54
|
|
|
260
|
|
|
—
|
|
|
(6
|
)
|
|
Entities affiliated with Discovery Capital
(4)
|
—
|
|
|
106
|
|
|
—
|
|
|
—
|
|
|
Scott D. Grimes
|
—
|
|
|
26
|
|
|
—
|
|
|
—
|
|
|
Lynne M. Laube
|
—
|
|
|
14
|
|
|
—
|
|
|
—
|
|
|
Entities affiliated with Mark A. Johnson
(5)
|
35
|
|
|
15
|
|
|
—
|
|
|
(6
|
)
|
|
John Klinck
|
6
|
|
|
—
|
|
|
—
|
|
|
(6
|
)
|
|
David Adams
|
3
|
|
|
—
|
|
|
—
|
|
|
(6
|
)
|
|
(1)
|
Consists of
159,207
shares of Series G’ redeemable convertible preferred stock issued to Aeroplan Holdings Europe Sàrl,
223,020
shares of Series G’ redeemable convertible preferred stock issued to Aimia EMEA Limited and
801,329
shares of common stock issued to Aimia EMEA Limited.
|
|
(2)
|
Consists of
27,988
shares of Series G redeemable convertible preferred stock purchased by Polaris Venture Partners V, L.P. (“PVP V”),
205,020
shares of Series G’ redeemable convertible preferred stock issued to PVP V,
545
shares of Series G redeemable convertible preferred stock purchased by Polaris Venture Partners Entrepreneurs’ Fund V, L.L. (“PVP EF V”),
3,995
shares of Series G’ redeemable convertible preferred stock issued to PVP EF V,
191
shares of Series G redeemable convertible preferred stock purchased by Polaris Venture Partners Founders’ Fund V, L.P. (“PVP FF V”),
1,404
shares of Series G’ redeemable convertible preferred stock issued to PVP FF V,
280
shares of Series G redeemable convertible preferred stock purchased by Polaris Venture Partners Special Founders’ Fund V, L.P. (“PVP SFF V”) and
2,050
shares of Series G’ redeemable convertible preferred stock issued to PVP SFF V. Polaris Venture Management Co. V, L.L.C. is a general partner of each of PVP V, PVP EF V, PVP FF V and PVP SFF V and may be deemed to have the sole voting and dispositive power over the shares held by PVP V, PVP EF V, PVP FF V and PVP SFF V. Bryce Youngren, a member of our board of directors, is a Managing Partner of Polaris Partners and may be deemed to share voting and dispositive power over the shares held by PVP V, PVP EF V, PVP FF V and PVP SFF V.
|
|
(3)
|
John V. Balen, a member of our board of directors, is a managing member of Canaan Partners VIII LLC, the general partner of Canaan VIII L.P. Mr. Balen does not have voting or investment power over any shares held directly by Canaan VIII L.P.
|
|
(4)
|
Consists of
95,272
shares of Series G’ redeemable convertible preferred stock issued to Discovery Opportunity Master Fund, Ltd. and
11,072
shares of Series G’ redeemable convertible preferred stock issued to Discovery Global Focus Master Fund, Ltd.
|
|
(5)
|
Consists of
15,045
shares of Series G’ redeemable convertible preferred stock issued to TTP Fund II, L.P.,
29,005
shares of Series G redeemable convertible preferred stock purchased by TTV Ivy Holdings, LLC and
5,801
shares of Series G redeemable convertible preferred stock purchased by Mr. Johnson. TTV Capital is a provider of management services to TTP GP II, LLC, which is a general partner of TTP Fund II, L.P. TTV Capital is the manager of TTV Ivy Holdings Manager, LLC, which is the general partner of TTV Ivy Holdings, LLC. Mark A. Johnson, a member of our board of directors, is a member of each of TTP GP II, LLC and TTV Ivy Holdings Managers, LLC and holds the title of partner of TTV Capital, and may be deemed to share voting and dispositive power over the shares held by TTP Fund II L.P. and TTV Ivy Holdings, LLC.
|
|
(6)
|
The maximum number of shares issuable to each investor upon the exercise of such warrants is equal to the number of shares of Series G redeemable convertible preferred stock set forth opposite such investor’s name in the table above. The actual number of shares issuable to each investor upon the exercise of such warrants is equal to the product obtained by multiplying the number of shares of Series G redeemable convertible preferred stock set forth opposite such investor’s name in the table above by a fraction, the numerator of which is the difference between
$68.9516
and the volume weighted average closing price of our common stock over the
30
trading days (or such lesser number of days as our common stock has been traded on the Nasdaq Global Market) prior to the date on which such warrants become exercisable and the denominator of which is such volume weighted average closing price.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Beginning balance
|
$
|
8,451
|
|
|
$
|
13,625
|
|
|
Deferred costs
|
—
|
|
|
250
|
|
||
|
Recoveries through FI Share, net of accumulated amortization
|
(963
|
)
|
|
(1,344
|
)
|
||
|
Amortization
|
(391
|
)
|
|
(412
|
)
|
||
|
Ending balance
|
$
|
7,097
|
|
|
$
|
12,119
|
|
|
|
March 31,
|
||||
|
|
2017
|
|
2018
|
||
|
Redeemable convertible preferred stock:
|
|
|
|
||
|
Series A-R
|
1,857
|
|
|
—
|
|
|
Series B-R
|
2,247
|
|
|
—
|
|
|
Series C-R
|
1,508
|
|
|
—
|
|
|
Series D-R
|
1,396
|
|
|
—
|
|
|
Series E-R
|
795
|
|
|
—
|
|
|
Series F-R
|
1,198
|
|
|
—
|
|
|
Series G
|
—
|
|
|
—
|
|
|
Series G’
|
—
|
|
|
—
|
|
|
Common stock options
|
2,170
|
|
|
2,379
|
|
|
Common stock warrants
|
1,227
|
|
|
927
|
|
|
Common stock warrants issuable pursuant to Series G Stock financing
|
—
|
|
|
1,286
|
|
|
Redeemable convertible preferred stock warrants
|
110
|
|
|
—
|
|
|
Restricted stock units
|
—
|
|
|
1,208
|
|
|
Restricted securities units
|
47
|
|
|
—
|
|
|
Convertible promissory notes
|
2,432
|
|
|
—
|
|
|
Common stock issuable pursuant to the ESPP
|
—
|
|
|
36
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Cardlytics Direct:
|
|
|
|
||||
|
Adjusted contribution
|
$
|
9,440
|
|
|
$
|
14,222
|
|
|
Plus: FI Share and other third-party costs
(1)
|
15,014
|
|
|
17,899
|
|
||
|
Revenue
|
$
|
24,454
|
|
|
$
|
32,121
|
|
|
Other Platform Solutions:
|
|
|
|
||||
|
Adjusted contribution
|
$
|
1,155
|
|
|
$
|
2
|
|
|
Plus: FI Share and other third-party costs
(1)
|
1,272
|
|
|
590
|
|
||
|
Revenue
|
$
|
2,427
|
|
|
$
|
592
|
|
|
Total:
|
|
|
|
||||
|
Adjusted contribution
|
$
|
10,595
|
|
|
$
|
14,224
|
|
|
Plus: FI Share and other third-party costs
(1)
|
16,286
|
|
|
18,489
|
|
||
|
Revenue
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
(1)
|
FI Share and other third party costs presented above excludes non-cash equity expense and amortization and impairment of deferred FI implementation costs, which are detailed below in our reconciliation of loss before income taxes to adjusted contribution.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Adjusted contribution
|
$
|
10,595
|
|
|
$
|
14,224
|
|
|
Minus:
|
|
|
|
||||
|
Non-cash equity expense included in FI Share
|
—
|
|
|
2,519
|
|
||
|
Amortization of deferred FI implementation costs
|
391
|
|
|
412
|
|
||
|
Delivery costs
|
1,553
|
|
|
1,943
|
|
||
|
Sales and marketing expense
|
7,232
|
|
|
8,216
|
|
||
|
Research and development expense
|
3,013
|
|
|
3,459
|
|
||
|
General and administration expense
|
4,689
|
|
|
6,582
|
|
||
|
Depreciation and amortization expense
|
765
|
|
|
910
|
|
||
|
Total other expense
|
5,415
|
|
|
10,238
|
|
||
|
Loss before income taxes
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
Revenue:
|
|
|
|
||||
|
United States
|
$
|
24,685
|
|
|
$
|
28,987
|
|
|
United Kingdom
|
2,196
|
|
|
3,726
|
|
||
|
Total
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
Property and equipment:
|
|
|
|
||||
|
United States
|
$
|
6,813
|
|
|
$
|
6,904
|
|
|
United Kingdom
|
506
|
|
|
459
|
|
||
|
Total
|
$
|
7,319
|
|
|
$
|
7,363
|
|
|
•
|
CPS
. Our primary and fastest growing pricing model is CPS, which we created to meet the media buying preferences of marketers. We generate revenue by charging a percentage (the "CPS Rate") , of all purchases from the marketer by consumers (1) who are served marketing and (2) subsequently make a purchase from the marketer during the campaign period, regardless of whether consumers select the marketing and thereby become eligible to earn the applicable Consumer Incentive. We set CPS Rates for marketers based on our expectation of the marketer’s return on spend for the relevant campaign. Additionally, we set the amount of the Consumer Incentives payable for each campaign based on our estimation of our ability to drive incremental sales for the marketer. We seek to optimize the level of Consumer Incentives to retain a greater portion of billings. However, if the amount of Consumer Incentives exceeds the amount of billings that we are paid by the applicable marketer we are still responsible for paying the total Consumer Incentive. This has occurred infrequently and has been immaterial in amount for each of the periods presented.
|
|
•
|
CPR
.
Our initial pricing model is CPR, where marketers specify and fund the Consumer Incentive and pay us a separate negotiated, fixed marketing fee (the "CPR Fee"), for each purchase that we generate. We generate revenue if the consumer (1) is served marketing, (2) selects the marketing and thereby becomes eligible to earn the applicable Consumer Incentive and (3) makes a qualifying purchase from the marketer during the campaign period. We set the CPR Fee for marketers based on our estimation of the marketers’ return on spend for the relevant campaign. The CPR Fee is either a percentage of qualifying purchases or a flat amount.
|
|
•
|
Ability to Drive Additional Revenue from Cardlytics Direct
. The revenue that we generate through our proprietary native bank advertising channels from each of our FI partners varies. This variance is typically a result of how long the program has been active, the user interface for the program and the FI’s efforts to promote the program. We continually work with FIs to improve their customers’ user experience, increase customer awareness, and leverage additional customer outreach channels like email. However, in certain cases, we may have little control over the design of the user interface that our FI partners choose to use or the extent to which they promote our solution to their customers. To the extent that our FI partners fail to increase engagement with our solutions within their customer bases, we may be unable to attract and retain marketers or their agencies and our revenue would suffer.
|
|
•
|
Ability to Increase Spend from Existing Marketers and Acquire New Marketers
. Our performance depends on our ability to continue to increase adoption of our solutions within our existing marketer base and attract new marketers that invest meaningfully in marketing through our solutions. Our ability to increase adoption among existing marketers is particularly important in light of our land-and-expand business model. We believe that we have the opportunity to expand our marketer base with a focus on attracting new brands, retailers, service providers and new categories of marketers that will invest significantly in the use of purchase intelligence. We believe that we also have the opportunity to increase adoption of our solutions across our existing marketers. In order to expand and further penetrate our marketer base, we have made, and plan to continue to make, investments in expanding our direct sales teams and indirect sales channels, and increasing our brand awareness. However, our ability to continue to grow our marketer base is dependent upon our ability to compete within the evolving markets in which we participate.
|
|
•
|
Ability to Expand our FI Partner Network
. Our ability to maintain and grow our revenue is contingent upon maintaining and expanding our relationships with our FI partners. Given our substantial investments to date in our intelligence platform and infrastructure, we believe that we will be able to add FIs to our network with modest incremental investment. Each new FI partner increases the size of our data asset, increasing the value of our solutions to both marketers and FIs that are already part of our network. Accordingly, we are focused on the continued expansion of our FI network to ensure that we have robust purchase data to support a broad array of incentive programs with respect to our Cardlytics Direct solution and to enrich our Other Platform Solutions. However, our sales and integration cycle with respect to our FI partners can be costly and long, and it is difficult to predict if or when we will be successful in generating revenue from a new FI relationship.
|
|
•
|
Ability to Innovate and Evolve Our Platform.
As we continue to grow our data asset and enhance our platform, we are developing new solutions and increasingly sophisticated analytical capabilities. Our future performance is significantly dependent on the investments that we make in our research and development efforts and in our ability to continue to innovate, improve functionality, and introduce new features and solutions that are compelling to our marketers and FIs. We intend to continue to invest in our platform, including by hiring top technical talent and focusing on innovation within our core technology.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands, except ARPU)
|
||||||
|
FI MAUs
|
51,914
|
|
|
58,684
|
|
||
|
ARPU
|
$
|
0.47
|
|
|
$
|
0.55
|
|
|
Adjusted contribution
(1)
|
$
|
10,595
|
|
|
$
|
14,224
|
|
|
Adjusted EBITDA
(1)
|
$
|
(4,912
|
)
|
|
$
|
(3,076
|
)
|
|
(1)
|
During the first quarter of 2017, adjusted contribution and adjusted EBITDA include the impact of a $1.5 million accrued expense related to an expected shortfall in meeting a minimum FI Share commitment. There was no corresponding accrued expense during the first quarter of 2018.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands)
|
||||||
|
Revenue
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
Minus:
|
|
|
|
||||
|
FI Share and other third-party costs
(1)
|
16,286
|
|
|
18,489
|
|
||
|
Adjusted contribution
(2)
|
$
|
10,595
|
|
|
$
|
14,224
|
|
|
(1)
|
FI Share and other third-party costs presented above excludes non-cash equity expense included in FI Share and amortization and impairment of deferred FI implementation costs, which are detailed below in our reconciliation of GAAP net loss to non-GAAP adjusted EBITDA.
|
|
(2)
|
During the first quarter of 2017, adjusted contribution includes the impact of a $1.5 million accrued expense related to an expected shortfall in meeting a minimum FI Share commitment. There was no corresponding accrued expense during the first quarter of 2018.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands)
|
||||||
|
Net loss
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
Plus:
|
|
|
|
||||
|
Interest expense, net
|
2,644
|
|
|
1,749
|
|
||
|
Depreciation and amortization expense
|
765
|
|
|
910
|
|
||
|
Stock-based compensation expense
|
983
|
|
|
2,900
|
|
||
|
Non-cash equity expense included in FI Share
|
—
|
|
|
2,519
|
|
||
|
Change in fair value of warrant liabilities
|
327
|
|
|
9,172
|
|
||
|
Change in fair value of convertible promissory notes
|
2,606
|
|
|
—
|
|
||
|
Foreign currency gain
|
(165
|
)
|
|
(683
|
)
|
||
|
Amortization and impairment of deferred FI implementation costs
|
391
|
|
|
412
|
|
||
|
Adjusted EBITDA
(1)
|
$
|
(4,912
|
)
|
|
$
|
(3,076
|
)
|
|
(1)
|
During the first quarter of 2017, adjusted EBITDA includes the impact of a $1.5 million accrued expense related to an expected shortfall in meeting a minimum FI Share commitment. There was no corresponding accrued expense during the first quarter of 2018.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands)
|
||||||
|
REVENUE
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
COSTS AND EXPENSES:
|
|
|
|
||||
|
FI Share and other third-party costs
|
16,677
|
|
|
21,420
|
|
||
|
Delivery costs
(1)
|
1,553
|
|
|
1,943
|
|
||
|
Sales and marketing expense
(1)
|
7,232
|
|
|
8,216
|
|
||
|
Research and development expense
(1)
|
3,013
|
|
|
3,459
|
|
||
|
General and administrative expense
(1)
|
4,689
|
|
|
6,582
|
|
||
|
Depreciation and amortization expense
|
765
|
|
|
910
|
|
||
|
Total costs and expenses
|
33,929
|
|
|
42,530
|
|
||
|
OPERATING LOSS
|
(7,048
|
)
|
|
(9,817
|
)
|
||
|
OTHER INCOME (EXPENSE):
|
|
|
|
||||
|
Interest expense, net
|
(2,644
|
)
|
|
(1,749
|
)
|
||
|
Change in fair value of warrant liabilities, net
|
(327
|
)
|
|
(9,172
|
)
|
||
|
Change in fair value of convertible promissory notes
|
(383
|
)
|
|
—
|
|
||
|
Change in fair value of convertible promissory notes—related parties
|
(2,223
|
)
|
|
—
|
|
||
|
Other income, net
|
162
|
|
|
683
|
|
||
|
Total other expense
|
(5,415
|
)
|
|
(10,238
|
)
|
||
|
LOSS BEFORE INCOME TAXES
|
(12,463
|
)
|
|
(20,055
|
)
|
||
|
INCOME TAX BENEFIT
|
—
|
|
|
—
|
|
||
|
NET LOSS
|
$
|
(12,463
|
)
|
|
$
|
(20,055
|
)
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands)
|
||||||
|
Delivery costs
|
$
|
41
|
|
|
$
|
85
|
|
|
Sales and marketing expense
|
344
|
|
|
943
|
|
||
|
Research and development expense
|
171
|
|
|
470
|
|
||
|
General and administrative expense
|
427
|
|
|
1,402
|
|
||
|
Total stock-based compensation expense
|
$
|
983
|
|
|
$
|
2,900
|
|
|
|
Three Months Ended
March 31,* |
||||
|
|
2017
|
|
2018
|
||
|
REVENUE
|
100
|
%
|
|
100
|
%
|
|
COSTS AND EXPENSES:
|
|
|
|
||
|
FI Share and other third-party costs
|
62
|
|
|
65
|
|
|
Delivery costs
|
6
|
|
|
6
|
|
|
Sales and marketing expense
|
27
|
|
|
25
|
|
|
Research and development expense
|
11
|
|
|
11
|
|
|
General and administration expense
|
17
|
|
|
20
|
|
|
Depreciation and amortization expense
|
3
|
|
|
3
|
|
|
Total costs and expenses
|
126
|
|
|
130
|
|
|
OPERATING LOSS
|
(26
|
)
|
|
(30
|
)
|
|
OTHER INCOME (EXPENSE):
|
|
|
|
||
|
Interest expense, net
|
(10
|
)
|
|
(5
|
)
|
|
Change in fair value of warrant liabilities
|
(1
|
)
|
|
(28
|
)
|
|
Change in fair value of convertible promissory notes
|
(1
|
)
|
|
—
|
|
|
Change in fair value of convertible promissory notes—related parties
|
(8
|
)
|
|
—
|
|
|
Other (expense) income, net
|
1
|
|
|
2
|
|
|
Total other expense
|
(20
|
)
|
|
(31
|
)
|
|
LOSS BEFORE INCOME TAXES
|
(46
|
)
|
|
(61
|
)
|
|
INCOME TAX BENEFIT
|
—
|
|
|
—
|
|
|
NET LOSS
|
(46
|
)%
|
|
(61
|
)%
|
|
|
|
*
|
Certain figures may not sum due to rounding.
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Revenue by solution:
|
|
|
|
|
|
|
|
|||||||
|
Cardlytics Direct
|
$
|
24,454
|
|
|
$
|
32,121
|
|
|
$
|
7,667
|
|
|
31
|
%
|
|
Other Platform Solutions
|
2,427
|
|
|
592
|
|
|
(1,835
|
)
|
|
(76
|
)%
|
|||
|
Total revenue
|
$
|
26,881
|
|
|
$
|
32,713
|
|
|
$
|
5,832
|
|
|
22
|
%
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
FI Share and other third-party costs by solution:
|
|
|
|
|
|
|
|
|||||||
|
Cardlytics Direct
|
$
|
15,014
|
|
|
$
|
17,899
|
|
|
$
|
2,885
|
|
|
19
|
%
|
|
Other Platform Solutions
|
1,272
|
|
|
590
|
|
|
(682
|
)
|
|
(54
|
)
|
|||
|
Other components of FI Share and other third-party costs:
|
|
|
|
|
|
|
|
|||||||
|
Non-cash equity expense included in FI Share
|
—
|
|
|
2,519
|
|
|
2,519
|
|
|
n/a
|
|
|||
|
Amortization and impairment of deferred FI implementation costs
|
391
|
|
|
412
|
|
|
21
|
|
|
5
|
%
|
|||
|
Total FI Share and other third-party costs
|
$
|
16,677
|
|
|
$
|
21,420
|
|
|
$
|
4,743
|
|
|
28
|
%
|
|
% of revenue
|
62
|
%
|
|
65
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Delivery costs
|
$
|
1,553
|
|
|
$
|
1,943
|
|
|
$
|
390
|
|
|
25
|
%
|
|
% of revenue
|
6
|
%
|
|
6
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Sales and marketing expense
|
$
|
7,232
|
|
|
$
|
8,216
|
|
|
$
|
984
|
|
|
14
|
%
|
|
% of revenue
|
27
|
%
|
|
25
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Research and development expense
|
$
|
3,013
|
|
|
$
|
3,459
|
|
|
$
|
446
|
|
|
15
|
%
|
|
% of revenue
|
11
|
%
|
|
11
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
General and administration expense
|
$
|
4,689
|
|
|
$
|
6,582
|
|
|
$
|
1,893
|
|
|
40
|
%
|
|
% of revenue
|
17
|
%
|
|
20
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Depreciation and amortization expense
|
$
|
765
|
|
|
$
|
910
|
|
|
$
|
145
|
|
|
19
|
%
|
|
% of revenue
|
17
|
%
|
|
20
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Interest expense, net
|
$
|
(2,644
|
)
|
|
$
|
(1,749
|
)
|
|
$
|
895
|
|
|
(34
|
)%
|
|
% of revenue
|
(10
|
)%
|
|
(5
|
)%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Change in fair value of warrant liabilities
|
$
|
(327
|
)
|
|
$
|
(9,172
|
)
|
|
$
|
(8,845
|
)
|
|
2,705
|
%
|
|
% of revenue
|
(1
|
)%
|
|
(28
|
)%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Change in fair value of convertible promissory notes
|
$
|
(383
|
)
|
|
$
|
—
|
|
|
$
|
383
|
|
|
(100
|
)%
|
|
% of revenue
|
(1
|
)%
|
|
—
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Change in fair value of convertible promissory notes—related parties
|
$
|
(2,223
|
)
|
|
$
|
—
|
|
|
$
|
2,223
|
|
|
(100
|
)%
|
|
% of revenue
|
(8
|
)%
|
|
—
|
%
|
|
|
|
|
|||||
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2017
|
|
2018
|
|
$
|
|
%
|
|||||||
|
|
(dollars in thousands)
|
|||||||||||||
|
Other (expense) income, net
|
$
|
162
|
|
|
$
|
683
|
|
|
$
|
521
|
|
|
322
|
%
|
|
% of revenue
|
1
|
%
|
|
2
|
%
|
|
|
|
|
|||||
|
|
December 31, 2017
|
|
March 31, 2018
|
||||
|
Cash and cash equivalents
|
$
|
21,262
|
|
|
$
|
89,785
|
|
|
Accounts receivable, net
|
48,348
|
|
|
39,907
|
|
||
|
Working capital
|
32,490
|
|
|
55,297
|
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2018
|
||||
|
|
(in thousands)
|
||||||
|
Cash and cash equivalents at beginning of period
|
$
|
22,968
|
|
|
$
|
21,262
|
|
|
Net cash used in operating activities
|
(5,824
|
)
|
|
(90
|
)
|
||
|
Net cash used in investing activities
|
(402
|
)
|
|
(794
|
)
|
||
|
Net cash from financing activities
|
7,565
|
|
|
69,232
|
|
||
|
Effect of exchange rates on cash and cash equivalents
|
46
|
|
|
175
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
24,353
|
|
|
$
|
89,785
|
|
|
•
|
lack of continued participation by financial institution ("FI") partners in our network or our failure to attract new FI partners;
|
|
•
|
failure by our FI partners to increase engagement with our solutions within their customer bases, improve their customers’ user experience, increase customer awareness, leverage additional customer outreach channels like email or otherwise promote our incentive programs on their websites and mobile applications, including by making the programs difficult to access or otherwise diminishing their prominence;
|
|
•
|
our failure to offer compelling incentives to our FIs’ customers;
|
|
•
|
any decline in demand for our Cardlytics Direct solution by marketers or their agencies;
|
|
•
|
the introduction by competitors of products and technologies that serve as a replacement or substitute for, or represent an improvement over, Cardlytics Direct;
|
|
•
|
FIs developing their own technology to support purchase intelligence marketing or other incentive programs;
|
|
•
|
technological innovations or new standards that our Cardlytics Direct solution does not address; and
|
|
•
|
sensitivity to current or future prices offered by us or competing solutions.
|
|
•
|
a change in the business strategy;
|
|
•
|
if there is a competitive reason to do so;
|
|
•
|
if new technical requirements arise;
|
|
•
|
consumer concern over use of purchase data;
|
|
•
|
if they choose to develop and use in-house solutions or use a competitive solution in lieu of our solutions; and
|
|
•
|
if legislation is passed restricting the dissemination, or our use, of the data that is currently provided to us or if judicial interpretations result in similar limitations.
|
|
•
|
dispose of assets;
|
|
•
|
complete mergers or acquisitions;
|
|
•
|
incur or guarantee indebtedness;
|
|
•
|
sell or encumber certain assets;
|
|
•
|
pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks;
|
|
•
|
make specified investments;
|
|
•
|
engage in different lines of business;
|
|
•
|
change certain key management personnel; and
|
|
•
|
engage in certain transactions with our affiliates.
|
|
•
|
our ability to attract and retain marketers, FI partners and bank processor and digital banking provider partners;
|
|
•
|
the amount and timing of revenue, operating costs and capital expenditures related to the operations and expansion of our business, particularly with respect to our efforts to attract new FI partners to our network;
|
|
•
|
the revenue mix between Cardlytics Direct and Other Platform Solutions, as well as between revenue generated from our operations in the U.S. and U.K.;
|
|
•
|
changes in the economic prospects of marketers, the industries or verticals that we primarily serve, or the economy generally, which could alter marketers’ spending priorities or budgets;
|
|
•
|
the termination or alteration of relationships with our FI partners in a manner that impacts ongoing or future marketing campaigns;
|
|
•
|
the amount and timing of expenses required to grow our business, including the timing of our payments of FI Share and FI Share commitments as compared to the timing of our receipt of payments from our marketers;
|
|
•
|
changes in demand for our solutions or similar solutions;
|
|
•
|
seasonal trends in the marketing industry, including concentration of marketer spend in the fourth quarter of the calendar year and declines in marketer spend in the first quarter of the calendar year;
|
|
•
|
competitive market position, including changes in the pricing policies of our competitors;
|
|
•
|
exposure related to our international operations and foreign currency exchange rates;
|
|
•
|
expenses associated with items such as litigation, regulatory changes, cyberattacks or security breaches;
|
|
•
|
the introduction of new technologies, products or solution offerings by competitors; and
|
|
•
|
costs related to acquisitions of other businesses or technologies.
|
|
•
|
maintain and expand our network of FI partners and bank processor and digital banking provider partners;
|
|
•
|
build and maintain long-term relationships with marketers and their agencies;
|
|
•
|
develop and offer competitive solutions that meet the evolving needs of marketers;
|
|
•
|
expand our relationships with FI partners to enable us to use their purchase data for new solutions;
|
|
•
|
improve the performance and capabilities of our solutions;
|
|
•
|
successfully expand our business;
|
|
•
|
successfully compete with other companies that are currently in, or may in the future enter, the markets for our solutions;
|
|
•
|
increase market awareness of our solutions and enhance our brand;
|
|
•
|
manage increased operating expenses as we continue to invest in our infrastructure to scale our business and operate as a public company; and
|
|
•
|
attract, hire, train, integrate and retain qualified and motivated employees.
|
|
•
|
tailor our solutions so that they that are attractive to businesses in such industries;
|
|
•
|
hire personnel with relevant industry-vertical experience to lead sales and services teams; and
|
|
•
|
develop sufficient expertise in such industries so that we can provide effective and meaningful marketing programs and analytics.
|
|
•
|
the failure of our network or software systems, or the network or software systems of our FI partners;
|
|
•
|
decisions by our FI partners to restrict our ability to collect data from them (which decision they may make at their discretion) or to refuse to implement the mechanisms that we request to ensure compliance with our legal obligations or technical requirements;
|
|
•
|
decisions by our FI partners to limit our ability to use their purchase data outside of the applicable banking channel;
|
|
•
|
decisions by our FIs’ customers to opt out of the incentive program or to use technology, such as browser settings, that reduces our ability to deliver relevant advertisements;
|
|
•
|
interruptions, failures or defects in our or our FI partners’ data collection, mining, analysis and storage systems;
|
|
•
|
changes in regulations impacting the collection and use of data, including the use of cookies;
|
|
•
|
changes in browser or device functionality and settings, and other new technologies, which impact our FI partners’ ability to collect and/or share data about their customers; and
|
|
•
|
changes in international laws, rules, regulations and industry standards or increased enforcement of international laws, rules, regulations, and industry standards.
|
|
•
|
localization of our solutions, including adaptation for local practices;
|
|
•
|
increased management, travel, infrastructure and legal compliance costs associated with having international operations;
|
|
•
|
fluctuations in currency exchange rates and related effect on our operating results;
|
|
•
|
longer payment cycles and difficulties in collecting accounts receivable or satisfying revenue recognition criteria, especially in emerging markets;
|
|
•
|
increased financial accounting and reporting burdens and complexities;
|
|
•
|
general economic conditions in each country or region;
|
|
•
|
economic uncertainty around the world;
|
|
•
|
compliance with foreign laws and regulations and the risks and costs of non-compliance with such laws and regulations;
|
|
•
|
compliance with U.S. laws and regulations for foreign operations, including the Foreign Corrupt Practices Act, the U.K. Bribery Act, import and export control laws, tariffs, trade barriers, economic sanctions and other regulatory or contractual limitations on our ability to sell our software in certain foreign markets, and the risks and costs of non-compliance;
|
|
•
|
heightened risks of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of financial statements and irregularities in financial statements;
|
|
•
|
difficulties in repatriating or transferring funds from or converting currencies in certain countries;
|
|
•
|
cultural differences inhibiting foreign employees from adopting our corporate culture;
|
|
•
|
reduced protection for intellectual property rights in some countries and practical difficulties of enforcing rights abroad; and
|
|
•
|
compliance with the laws of foreign taxing jurisdictions and overlapping of different tax regimes.
|
|
•
|
an acquisition may negatively affect our business, financial condition, operating results or cash flows because it may require us to incur charges or assume substantial debt or other liabilities, may cause adverse tax consequences or unfavorable accounting treatment, may expose us to claims and disputes by third parties, including intellectual property claims and disputes, or may not generate sufficient financial return to offset additional costs and expenses related to the acquisition;
|
|
•
|
we may encounter difficulties or unforeseen expenditures in integrating the business, technologies, products, personnel or operations of any company that we acquire, particularly if key personnel of the acquired company decide not to work for us;
|
|
•
|
an acquisition, whether or not consummated, may disrupt our ongoing business, divert resources, increase our expenses and distract our management;
|
|
•
|
an acquisition may result in a delay or reduction of purchases for both us and the company that we acquired due to uncertainty about continuity and effectiveness of solution from either company;
|
|
•
|
we may encounter difficulties in, or may be unable to, successfully sell any acquired products or solutions;
|
|
•
|
an acquisition may involve the entry into geographic or business markets in which we have little or no prior experience or where competitors have stronger market positions;
|
|
•
|
challenges inherent in effectively managing an increased number of employees in diverse locations;
|
|
•
|
the potential strain on our financial and managerial controls and reporting systems and procedures;
|
|
•
|
potential known and unknown liabilities associated with an acquired company;
|
|
•
|
our use of cash to pay for acquisitions would limit other potential uses for our cash;
|
|
•
|
if we incur debt to fund such acquisitions, such debt may subject us to material restrictions on our ability to conduct our business as well as financial maintenance covenants;
|
|
•
|
the risk of impairment charges related to potential write-downs of acquired assets or goodwill in future acquisitions; and
|
|
•
|
to the extent that we issue a significant amount of equity or convertible debt securities in connection with future acquisitions, existing stockholders may be diluted and earnings (loss) per share may decrease (increase).
|
|
•
|
pay substantial damages, including treble damages, if we are found to have willfully infringed a third party’s patents or copyrights;
|
|
•
|
cease developing or selling solutions that rely on technology that is alleged to infringe or misappropriate the intellectual property of others;
|
|
•
|
expend additional development resources to attempt to redesign our solutions or otherwise develop non-infringing technology, which may not be successful;
|
|
•
|
enter into potentially unfavorable royalty or license agreements in order to obtain the right to use necessary technologies or intellectual property rights; and
|
|
•
|
indemnify our FI partners and other third parties.
|
|
•
|
actual or anticipated fluctuations in our financial condition and operating results;
|
|
•
|
variance in our financial performance from expectations of securities analysts or investors;
|
|
•
|
changes in the prices of our solutions;
|
|
•
|
changes in laws or regulations applicable to our solutions;
|
|
•
|
announcements by us or our competitors of significant business developments, acquisitions or new offerings;
|
|
•
|
our involvement in litigation;
|
|
•
|
our sale of our common stock or other securities in the future;
|
|
•
|
changes in senior management or key personnel;
|
|
•
|
trading volume of our common stock;
|
|
•
|
changes in the anticipated future size and growth rate of our market; and
|
|
•
|
general economic, regulatory and market conditions.
|
|
•
|
authorize our board of directors to issue preferred stock without further stockholder action and with voting liquidation, dividend and other rights superior to our common stock;
|
|
•
|
require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent, and limit the ability of our stockholders to call special meetings;
|
|
•
|
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for director nominees;
|
|
•
|
establish that our board of directors is divided into three classes, with directors in each class serving three-year staggered terms;
|
|
•
|
require the approval of holders of two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or amend or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors and the ability of stockholders to take action by written consent or call a special meeting;
|
|
•
|
prohibit cumulative voting in the election of directors; and
|
|
•
|
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.
|
|
|
|
|
|
Incorporated by Reference
|
|
|
||||||
|
Exhibit
|
|
Exhibit Description
|
|
Schedule
/Form
|
|
File
Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed
Herewith
|
|
3.1
|
|
|
S-1
|
|
333-222531
|
|
3.2
|
|
1/12/2018
|
|
|
|
|
3.2
|
|
|
S-1
|
|
333-222531
|
|
3.4
|
|
1/12/2018
|
|
|
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
32.1*
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
101.ins
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.sch
|
|
XBRL Taxonomy Schema Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.cal
|
|
XBRL Taxonomy Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.def
|
|
XBRL Taxonomy Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.lab
|
|
XBRL Taxonomy Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.pre
|
|
XBRL Taxonomy Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
Cardlytics, Inc.
|
|
|
|
|
|
|
|
|
Date:
|
May 10, 2018
|
|
By:
|
/s/ Scott D. Grimes
|
|
|
|
|
|
Scott D. Grimes
|
|
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
|
|
Date:
|
May 10, 2018
|
|
By:
|
/s/ David T. Evans
|
|
|
|
|
|
David T. Evans
|
|
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|